drugset / Trial / NCT01057212
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Phase 2
Terminated
6 enrolled
Providence Health & Services
Bristol-Myers Squibb · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, open-label, single arm phase II trial of the combination of bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC progressive after first or second-line therapy. The main objective is to evaluate the progression-free survival in patients with advanced or metastatic non-squamous NSCLC being treated with ixabepilone and bevacizumab.
Timeline
- Start
- 2010-02
- Primary completion
- 2013-12
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Ixabepilone | Small molecule | 16 mg/m2 | Intravenous |
| Subject | Ixabepilone | Small molecule | 20 mg/m2 | Intravenous |